Cargando…

A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS

BACKGROUND: The treatment strategies for Myelodysplastic Syndromes (MDS) are usually based on the risk stratification system. However, few risk signatures which integrate the revised international prognostic scoring system (IPSS-R) with gene mutations can be easily applied in the real world. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Siyu, Xia, Jingya, Tian, Yulu, Zi, Jie, Ge, Zheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866647/ https://www.ncbi.nlm.nih.gov/pubmed/33549060 http://dx.doi.org/10.1186/s12885-021-07864-y

Ejemplares similares

Risk prediction in MDS: independent validation of the IPSS-M—ready for routine?
por: Baer, Constance, et al.
Publicado: (2023)

P725: BATTLE OF THE GIANTS – COMPARISON OF IPSS-M AND IPSS-R IN PATIENTS WITH MISSING MOLECULAR DATA EXCEPT TP53 MUTATION STATUS FROM THE DÜSSELDORF MDS REGISTRY
por: Schulz, Felicitas, et al.
Publicado: (2023)

The impact of iron chelation therapy on patients with lower/intermediate IPSS MDS and the prognostic role of elevated serum ferritin in patients with MDS and AML: A meta-analysis
por: Yang, Yuan, et al.
Publicado: (2019)

Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome
por: Benites, Bruno Deltreggia, et al.
Publicado: (2013)

IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes
por: Wu, Junying, et al.
Publicado: (2022)

Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC
por: Huber, Sandra, et al.
Publicado: (2023)

The Absolute Monocyte Count at Diagnosis Affects Prognosis in Myelodysplastic Syndromes Independently of the IPSS-R Risk Score
por: Silzle, Tobias, et al.
Publicado: (2023)

P727: REFINING RISK STRATIFICATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A COMPREHENSIVE ASSESSMENT OF THE IPSS-M AND OTHER MOLECULARLY INTEGRATED PROGNOSTIC MODELS
por: Aguirre, Luis E., et al.
Publicado: (2023)

Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts
por: Todisco, Gabriele, et al.
Publicado: (2023)

Bone marrow CD3 (+) CD56 (+) regulatory T lymphocytes (T(R3) (−56) cells) are inversely associated with activation and expansion of bone marrow cytotoxic T cells in IPSS‐R very‐low/low risk MDS patients
por: Leone, Stefania, et al.
Publicado: (2022)

Evaluation of new IPSS-Molecular model and comparison of different prognostic systems in patients with myelodysplastic syndrome
por: Ma, Jiale, et al.
Publicado: (2023)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
por: Huber, Sandra, et al.
Publicado: (2023)

Elevated mature monocytes in bone marrow accompanied with a higher IPSS-R score predicts a poor prognosis in myelodysplastic syndromes
por: Wu, An, et al.
Publicado: (2021)

Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome
por: Suh, Koung Jin, et al.
Publicado: (2016)

Effect of Depth of Electroacupuncture on the IPSS of Patients with Benign Prostatic Hyperplasia
por: Yuan, Hongwei, et al.
Publicado: (2019)

Impact of IPSS-M implementation in real-life clinical practice
por: Zamanillo, Irene, et al.
Publicado: (2023)

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
por: Sekeres, M A, et al.
Publicado: (2014)

PB2012: DESCRIBING TREATMENT PATTERNS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ACCORDING TO IPSS-R RISK CATEGORY
por: Corry, Sorcha, et al.
Publicado: (2023)

Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
por: Barbui, Tiziano, et al.
Publicado: (2022)

The Wilms’ tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy
por: Gallo, Daniela, et al.
Publicado: (2016)

P728: EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
por: Urrutia, Samuel, et al.
Publicado: (2023)

International prostate symptom score (IPSS) change and changing factor in intensity-modulated radiotherapy combined with androgen deprivation therapy for prostate cancer
por: Tomita, Natsuo, et al.
Publicado: (2015)

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15)
por: Aghdam, Nima, et al.
Publicado: (2020)

P1047: AIPSS-MF MACHINE LEARNING MODEL AS USEFUL PROGNOSTIC SCORE COMPARED TO IPSS IN THE SETTING OF MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB
por: Duminuco, Andrea, et al.
Publicado: (2023)

Can we make the preparation of MDS more efficient?
por: Salvachua, B
Publicado: (2019)

Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients
por: Silzle, Tobias, et al.
Publicado: (2019)

Integrating cell cycle score for precise risk stratification in ovarian cancer
por: Chen, Lingying, et al.
Publicado: (2022)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

MDS-Net: Multi-Scale Depth Stratification 3D Object Detection from Monocular Images
por: Xie, Zhouzhen, et al.
Publicado: (2022)

What Clonal Hematopoiesis Can Teach Us About MDS
por: Chan, Irenaeus C. C., et al.
Publicado: (2022)

Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes
por: Papageorgiou, Sotirios G., et al.
Publicado: (2020)

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
por: Urrutia, Samuel, et al.
Publicado: (2023)

Evaluating International Prostate Symptom Score (IPSS) in Accuracy for Predicting Post-Operative Urinary Retention After Elective Cataract Surgery: A Prospective Study
por: Fazeli, Faramarz, et al.
Publicado: (2015)

Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia
por: Garcia-Manero, Guillermo, et al.
Publicado: (2016)

Implementation of Miettinen-Nurminen score method with or without stratification in R
por: Lee, Moon Hee, et al.
Publicado: (2022)

Evaluation of different scoring systems and gene mutations for the prognosis of myelodysplastic syndrome (MDS) in Chinese population
por: Du, Meng-yi, et al.
Publicado: (2020)

Prospective comparison of the novel visual prostate symptom score (VPSS) versus the international prostate symptom score (IPSS), and assessment of patient pain perception with regard to transrectal ultrasound guided prostate biopsy
por: Els, M., et al.
Publicado: (2019)

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
por: Kuendgen, A., et al.
Publicado: (2020)

Of Screening, Stratification, and Scores
por: Knoppers, Bartha M., et al.
Publicado: (2021)

ATS MD’s in 2016
por: Fartoukh, Stephane, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4buk11291v4mfscfaqa1vtdqvm